<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04643093</url>
  </required_header>
  <id_info>
    <org_study_id>OP-1PC111-301</org_study_id>
    <nct_id>NCT04643093</nct_id>
  </id_info>
  <brief_title>Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia</brief_title>
  <official_title>Orient Pharma Co., Ltd.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orient Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orient Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to evaluate whether the efficacy of 1PC111 is superior to pitavastatin and&#xD;
      ezetimibe in patients with primary hypercholesterolemia or mixed dyslipidemia in the 12 week&#xD;
      treatment period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of 1PC111 is superior to pitavastatin and ezetimibe in patients</measure>
    <time_frame>12 week treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The efficacy and safety profile of 1PC111 , pitavastatin and ezetimibe during the treatment period and 2 week follow up period.</measure>
    <time_frame>12 week treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <condition>Mixed Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Pitavastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pitavastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ezetimibe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1PC111</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1PC111</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>Pitavastatin, QD</description>
    <arm_group_label>Pitavastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Ezetimibe, QD</description>
    <arm_group_label>Ezetimibe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1PC111</intervention_name>
    <description>1PC111, QD</description>
    <arm_group_label>1PC111</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Primary hypercholesterolemia or mixed dyslipidemia&#xD;
&#xD;
          2. Subject meeting All of the following diagnoses at Baseline visit:&#xD;
&#xD;
               -  TG≦350 mg/dL&#xD;
&#xD;
               -  ALT and AST≦ 2.5 times of upper limit of normal (ULN) with no acute liver disease&#xD;
&#xD;
               -  Creatine kinase (CK) concentration≦2 times of UL N&#xD;
&#xD;
               -  Creatinine≦1.5 mg/dL&#xD;
&#xD;
          3. Subject who is willing and able to provide inform ed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female who is or intends to be pregnant or breast feeding, or has childbearing&#xD;
             potential but without effective contraception.&#xD;
&#xD;
          2. Subject with documented HIV&#xD;
&#xD;
          3. Subject with uncontrolled hypothyroidism according to the investigator's judgment&#xD;
&#xD;
          4. Subject with unstable cardiovascular disease (CVD), including but not limited to&#xD;
             congestive heart failure (CHF) defined as New York Heart Association class III or IV,&#xD;
             unstable angina, unstable arrhythmia according to the investigator's judgment&#xD;
&#xD;
          5. Subject with unstable hepatic or biliary disorders, including but not limited to acute&#xD;
             hepatitis, acute exacerbation of chronic hepatitis, liver cirrhosis, liver cancer,&#xD;
             jaundice , and chronic hepatitis B or C under antiviral therapy&#xD;
&#xD;
          6. Subject with the following medical histories:&#xD;
&#xD;
               -  History of malignancy, exceptions made for the following malignancies: a)those&#xD;
                  determined to be cured or in remission for ≥ 5 years, b) curatively resected&#xD;
                  basal cell or squamous cell skin cancers, c) cervical cancer in situ, or resected&#xD;
                  colonic polyps&#xD;
&#xD;
               -  Acute coronary syndrome with or without cardiac catheterization within the past 9&#xD;
                  months&#xD;
&#xD;
               -  Therapeutic cardiac catheterization (due to reasons other than acute coronary&#xD;
                  syndrome) within the past 6 months&#xD;
&#xD;
          7. Any unstable comorbidities or clinical conditions , including laboratory abnormalities&#xD;
             which could lead to unacceptable risk to subject or confound data interpretation , per&#xD;
             investigatiors judgment&#xD;
&#xD;
          8. Use any lipid lowering agent within 6 weeks prior to initiating the study treatment (&#xD;
             recheck this criterion at Day 1)&#xD;
&#xD;
          9. Use cyclosporine within 6 weeks prior to initiating the study treatment (recheck this&#xD;
             criterion at Day 1)&#xD;
&#xD;
         10. Use any investigational product within 6 weeks prior to initiating the study treatment&#xD;
             ( recheck this criterion at Day 1)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Paratus Clinical Research Western Sydney</name>
      <address>
        <city>Blacktown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Beaches Clinical Research</name>
      <address>
        <city>Brookvale</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research</name>
      <address>
        <city>Camberwell</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paratus Clinical Research Central Coast</name>
      <address>
        <city>Kanwal</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Trials - Waitemata Ltd.</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Trials Totara</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Trials Group Ltd</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Clinical Trials Waikato</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Trials Tasman</name>
      <address>
        <city>Nelson</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Clinical Trials Rotorua</name>
      <address>
        <city>Rotorua</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Culloden Research Ltd.</name>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiayi Christian Hospital</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E-Da Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital of the C.G.M.F.</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuang Tien General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tainan Municipal Hospital (Managed By Show Chwan Medical Care Corporation)</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cathay General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheng Hsin General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shin Kong Wu Ho-Su Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tamsui Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation- LinKuo Branch</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 22, 2020</study_first_submitted>
  <study_first_submitted_qc>November 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Hypercholesterolemia</keyword>
  <keyword>Mixed Dyslipidemias</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

